For US residents only.

Lung Cancer (CANOPY-2)

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2).

Overview

This Study Is Recruiting: Phase III Estimated Start Date: [January 23, 2019] Estimated Completion Date: [March 8, 2021] Novartis Reference Number: CACZ885V2301
Condition: Lung Cancer Interventions: Canakinumab, docetaxel, placebo Estimated Enrollment: [240 participants] ClinicalTrials.gov Identifier: NCT03626545
This Study Is Recruiting: Phase III Estimated Start Date: [January 23, 2019]
Estimated Completion Date: [March 8, 2021] Novartis Reference Number: CACZ885V2301
Condition: Lung Cancer Interventions: Canakinumab, docetaxel, placebo
Estimated Enrollment: [240 participants] ClinicalTrials.gov Identifier: NCT03626545

Study Goal

This phase III study is designed to evaluate the role of IL-1β inhibition in combination with docetaxel in subjects with advanced NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy. The randomized III part will be preceded by a safety run-in part in which the recommended dose of the combination of canakinumab and docetaxel will be confirmed.

All drugs are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Eligibility

Participants may be eligible to participate if they:

  • Are 18 years or older
  • Have been diagnosed with advanced Stage IIIB or metastatic NSCLC
  • Have previously received 1 prior platinum-based chemotherapy and 1 prior PD-(L)1 inhibitor therapy for locally advanced or metastatic disease
  • Meet other eligibility criteria

If you're interested in this clinical study, your doctor can help evaluate whether you are eligible to participate. Ask your doctor if your medical history or other treatments you're receiving may conflict with the study protocol. If you meet the eligibility criteria and agree to participate in the study: You will be required to sign an informed consent form (ICF). The ICF contains information about the study, which your doctor can help explain to you before you sign. Your doctor will need to complete the necessary tests to see if you are eligible. As with all clinical trials, you have the right to leave the study at any time, for any reason.

Find a Trial Site Location

To find a list of all our recruiting site locations, enter your address below.

×
0 results listed in order of distance from

Still Have a Question?

Are you a Patient or Caregiver looking for more information?

Are you a Health Care Professional looking for more information?

To view eligibility requirements for this trial, arms and interventions, trial sites and study design, please click to visit this trial on www.clinicaltrials.gov.

Other lung cancer trials you might be interested in:

A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC) (CANOPY A)

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)

Definitions:
CANOPY - CANakinumab Outcomes in Patients with NSCLC StudY, ICF - informed consent form, IL-1β - interleukin-1-beta, NSCLC - non-small cell lung cancer, PD-(L)1 - programmed death-ligand 1

Last Updated: July 29, 2019

8/19 M-GON-1216064